ODAC Report Card: Six Takeaways From Accelerated Approval Reviews Of Checkpoint Inhibitors

 
• By Sue Sutter
Hurdler
PD-1/L1 sponsors successfully hurdled an FDA panel review four out of six times. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers